Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial

Key Takeaways

• Celcuity’s VIKTORIA-1 Phase 3 trial successfully met its primary endpoint, demonstrating clinically meaningful progression-free survival improvement with gedatolisib
• The positive results target PIK3CA mutant cancer patients, representing a genetically defined precision medicine approach
• Detailed efficacy and safety data will be presented at the 2026 ASCO Annual Meeting in a late-breaking abstract oral session

---

Minneapolis-based Celcuity Inc. (Nasdaq: CELC) announced on May 1, 2026, that its Phase 3 VIKTORIA-1 trial achieved its primary endpoint, showing clinically meaningful improvement in progression-free survival for PIK3CA mutant cancer patients treated with gedatolisib.

The clinical-stage biotechnology company’s PI3K/mTOR dual inhibitor demonstrated significant efficacy in the genetically defined patient population, marking a major milestone in precision oncology treatment development.

Trial Design and Patient Population

The VIKTORIA-1 study evaluated gedatolisib in both triplet and doublet combination regimens specifically in patients with PIK3CA mutations. PIK3CA mutations occur in approximately 20-40% of certain cancer types and have been associated with resistance to standard therapies, creating an urgent need for targeted treatment options.

Gedatolisib’s mechanism as a PI3K/mTOR dual inhibitor allows it to simultaneously target multiple pathways involved in cancer cell growth and survival, potentially offering advantages over single-pathway inhibitors currently available.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for oncology, with gedatolisib most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Competitive Landscape and Market Impact

The positive VIKTORIA-1 results position gedatolisib to compete with established PIK3CA-targeted therapies including Novartis’s alpelisib, AstraZeneca’s capivasertib, and Genentech/Roche’s inavolisib. The PIK3CA-targeted therapy market represents a significant opportunity in precision oncology, with the potential for first-line treatment applications.

Celcuity’s approach of targeting specific genetic mutations aligns with the broader trend toward biomarker-driven cancer treatment, which has shown improved patient outcomes and reduced unnecessary exposure to ineffective therapies.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Clinical Development Timeline

The company plans to present comprehensive efficacy and safety data from both the gedatolisib triplet and doublet regimens at the 2026 ASCO Annual Meeting during a late-breaking abstract oral session. This high-profile presentation venue indicates the clinical significance of the trial results within the oncology community.

Following the ASCO presentation, Celcuity will likely pursue regulatory submissions based on the Phase 3 data, though specific timelines for FDA filing have not been disclosed.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for oncology pricing, access, and launch sequencing.

Investment and Development Implications

The successful primary endpoint achievement represents a significant value inflection point for Celcuity, validating years of clinical development investment in gedatolisib. The results support the company’s precision medicine strategy and may accelerate partnership discussions with larger pharmaceutical companies seeking to expand their oncology portfolios.

Key development risks remain, including the safety profile of combination regimens, manufacturing scalability for potential commercialization, and competitive positioning against established treatments. However, the clinically meaningful progression-free survival improvement suggests gedatolisib may offer differentiated benefits for PIK3CA mutant patients.

IntelligenceStrategic Takeaways▾

Celcuity’s VIKTORIA-1 Phase 3 trial successfully met its primary endpoint, demonstrating clinically meaningful progression-free survival improvement with gedatolisib The positive results target PIK3CA mutant cancer patients, representing a genetically defined precision medicine approach Detailed efficacy and safety data will be presented at the 2026 ASCO Annual Meeting in a late-breaking abstract oral session

Future Development Opportunities

Beyond the current indication, successful VIKTORIA-1 results may support label expansion opportunities to other PIK3CA mutant cancer types. The dual inhibitor mechanism could also enable combination strategies with immunotherapies or other targeted agents, potentially broadening the addressable patient population.

The precision medicine approach demonstrated in VIKTORIA-1 reinforces the importance of genetic testing in cancer treatment selection, likely supporting broader adoption of PIK3CA mutation testing in clinical practice.

---

Frequently Asked Questions

What does this mean for PIK3CA mutant cancer patients?

Patients with PIK3CA mutations may have a new treatment option that specifically targets their genetic mutation. The trial showed clinically meaningful improvement in progression-free survival, meaning patients experienced longer periods without cancer progression compared to standard treatments.

When will gedatolisib be available to patients?

Gedatolisib is not yet approved. Celcuity will present detailed trial data at the 2026 ASCO Annual Meeting, after which they will likely file for regulatory approval. The FDA review process typically takes 6-12 months, so availability could be in late 2026 or 2027 if approved.

How does gedatolisib compare to existing PIK3CA-targeted treatments?

Gedatolisib is a PI3K/mTOR dual inhibitor, potentially offering advantages over single-pathway inhibitors like alpelisib. The dual mechanism may provide more comprehensive pathway blockade, though direct comparative studies would be needed to establish relative efficacy and safety profiles.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
• Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint